

# Elena Buzzetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4532168/publications.pdf>

Version: 2024-02-01

31  
papers

2,534  
citations

623188

14  
h-index

433756

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Collagen proportionate area predicts long-term mortality in patients with alcoholic hepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 663-668.	0.4	3
2	Iron in Porphyrias: Friend or Foe?. <i>Diagnostics</i> , 2022, 12, 272.	1.3	4
3	Comparison of pointâ€shear wave elastography (ElastPQ) and transient elastography (FibroScan) for liver fibrosis staging in patients with nonâ€alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 2195-2203.	1.9	3
4	Establishing Reliability Criteria for Liver ElastPQ Shear Wave Elastography (ElastPQ-SWE): Comparison Between 10, 5 and 3 Measurements. <i>Ultraschall in Der Medizin</i> , 2021, 42, 204-213.	0.8	9
5	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	1.0	37
6	Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013156.	1.5	13
7	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013157.	1.5	7
8	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. <i>Journal of Hepatology</i> , 2021, 75, 506-513.	1.8	40
9	Genetic iron overload disorders. <i>Molecular Aspects of Medicine</i> , 2020, 75, 100896.	2.7	28
10	Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?. <i>European Journal of Internal Medicine</i> , 2020, 79, 101-107.	1.0	22
11	Collagen proportionate area predicts clinical outcomes in patients with alcoholâ€related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1728-1739.	1.9	27
12	Risk of Kidney Dysfunction IN Nafld. <i>Current Pharmaceutical Design</i> , 2020, 26, 1045-1061.	0.9	12
13	Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes nonâ€alcoholic fatty liver diseaseâ€”authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 339-339.	1.9	1
14	Cardiovascular morbidity and mortality is increased postâ€liver transplantation even in recipients with no preâ€existing risk factors. <i>Liver International</i> , 2019, 39, 1557-1565.	1.9	18
15	Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements. <i>Digestive and Liver Disease</i> , 2019, 51, 911-913.	0.4	9
16	Editorial: collagen proportionate area as a prognostic indicator in NAFLDâ€”authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1454-1455.	1.9	0
17	Collagen proportionate area is an independent predictor of longâ€term outcome in patients with nonâ€alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1214-1222.	1.9	55
18	Evaluating the association of serum ferritin and hepatic iron with disease severity in nonâ€alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1325-1334.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. <i>Internal and Emergency Medicine</i> , 2019, 14, 423-431.	1.0	17
20	Pharmacological interventions for acute hepatitis C infection. <i>The Cochrane Library</i> , 2018, 12, CD011644.	1.5	2
21	Interventions for hereditary haemochromatosis. <i>The Cochrane Library</i> , 2017, 3, CD011647.	1.5	6
22	Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. <i>Scientific Reports</i> , 2017, 7, 40977.	1.6	14
23	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease). <i>The Cochrane Library</i> , 2017, 2017, CD011646.	1.5	13
24	Pharmacological interventions for acute hepatitis B infection. <i>The Cochrane Library</i> , 2017, 2017, CD011645.	1.5	12
25	Gender differences in liver disease and the drug-dose gender gap. <i>Pharmacological Research</i> , 2017, 120, 97-108.	3.1	66
26	Pharmacological interventions for acute hepatitis C infection. <i>The Cochrane Library</i> , 2017, 3, CD011644.	1.5	1
27	Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 549-550.	3.7	2
28	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 184-194.	0.6	21
29	The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1038-1048.	1.5	1,977
30	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11044.	1.4	25
31	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	41